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ABSTRACT 
 
Background: Chronic infection with hepatitis C virus (HCV) decreases health-related 
quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL 
of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated 
interferon and ribavirin, in addition to IL28B polymorphisms. 
Methods: The present study enrolled 228 CHC patients, and assessed their HRQOLs 
prospectively with the 36-item short-form health survey.  
Results: The patients with chronic hepatitis C have lower physical HRQOL status than the 
general population (P = 0.037, the Z test). The patients with advanced liver diseases 
exhibited further decreases in HRQOL (P = 0.036, Spearman's rank correlation coefficient). 
The score of total HRQOL was significantly lower in the group with sustained virological 
response (SVR) to the therapy with pegylated interferon and ribavirin than the non-SVR 
group (P = 0.031, the Mann-Whitney U test), with significantly lower scores of mental 
component and its comprising subscales in the SVR group. Stepwise multivariate logistic 
regression analysis showed that low HRQOL score ≤400 points was significantly associated 
with SVR (odds ratio = 2.4, P = 0.013), independently from high platelet counts, low HCV 
RNA, favorable SNP type of IL28B, and HCV serotype 2. The patients with low HRQOL 
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score will had significantly less decrease in HRQOL score by 4 weeks of the treatment than 
those with high HRQOL score at baseline (P = 0.0045). 
Conclusions: HRQOL is one of the significant predictor of the outcomes of therapy with 
pegylated interferon and ribavirin independently from IL28B polymorphism. 
 
Key words: Interferon, QOL, and HCV 
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INTRODUCTION 
More than 170 million people worldwide are infected with hepatitis C virus (HCV) infection, 
which causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [1, 2]. The 
combination with pegylated Interferon-α (PegIFN) and ribavirin (RBV) is widely used for the 
treatment of patients with chronic hepatitis C [3]. Recent therapeutic regimens using directly 
acting antiviral agents with PegIFN and RBV have improved sustained virological response 
(SVR) rate up to 80% for the patients with HCV genotype 1 [4-6].  
The health-related quality of life (HRQOL) has been studied in patients with various 
diseases, such as gastrointestinal disorders, diabetes mellitus, heart disease and 
depression, and is profoundly associated with disease severity and progression [7-11]. In 
terms of HCV, chronic viral infection itself decreases the HRQOL of the patients [12], and 
the HRQOL may affect the outcome of interferon therapy [13-20]. However, the impact of 
HRQOL has not been well understood in comparison with other predictive factors such as 
the single-nucleotide polymorphism (SNP) of IL28B or HCV serogroup. 
The present study evaluated the HRQOL of the patients with chronic hepatitis C 
prospectively before and during the combinations of PegIFN and RBV, in order to clarify the 
impact of HRQOL on the outcomes of IFN therapy. Our results indicated that total HRQOL 
before the therapy is significantly associated with sustained viral response for the patients 
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with chronic hepatitis C, independently of the SNP types of IL28B and HCV serogroup.  
 
METHODS 
Patients 
The present study enrolled the patients with chronic HCV infection, of whom the HRQOLs 
were evaluated at Okayama University hospital between 2006 and 2011. Patients 
co-infected with hepatitis B virus or human immunodeficiency virus, and patients with 
complicating autoimmune liver diseases were not included in the study. Hepatocellular 
carcinoma was ruled out by means of dynamic computed tomography or magnetic 
resonance imaging, combined with measurement of the serum levels of alpha-fetoprotein, 
and des-γ-carboxy prothrombin. The study was performed in accordance with the Helsinki 
Declaration, and all the protocols were approved by the ethics committees of the institute. 
All patients provided informed consent before enrollment into the study. This study was 
registered for University Hospital Medical Information NetworkClinical Trials Registry 
(UMIN 000001031).  
 
Interferon therapy 
The patients received a combination of PegIFN-α2a (180 µg) or PegIFN-α2b (1.5 µg/kg of 
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body weight) by subcutaneous injection every week with RBV (600–1000 mg daily, 
according to body weight). The doses of PegIFN and RBV were individually reduced during 
the treatment whenever needed to lessen adverse effects, and these dose reductions were 
performed according to the labeling.  
 
Measurement of health-related quality of life 
All the patients were evaluated to determine their HRQOL score before the treatment, by 
using the 36-item short-form health survey (SF-36) version 2nd [21-23]. One hundred and 
seventy-six patients were longitudinally evaluated for changes of HRQOL score. Their 
HRQOL scores were assessed before the treatment, at 4 weeks of treatment, at the end of 
treatment, and at 24 weeks after treatment. The SF-36 consists of 8 subscales (physical 
function, role-physical, bodily pain, general health, vitality, social function, role-emotional, 
and mental health), with each subscale having been adjusted so that a score of 50 
corresponds to the mean value for that subscale in the general population. The general 
population in the SF-36 for Japanese is established based on the data of 6053 healthy 
Japanese residents with 20 to 80 years of age [23]. The mean scores of total HRQOL of the 
general population were quoted as 400 points. The scores of physical, mental, and 
role-social components were also estimated according to the proposal for the general 
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population in the previous report [23].  
 
Diagnosis of liver histology 
Liver fibrosis stage and hepatitis activity grade were assigned for all the patients by two 
pathologists according to the criteria of Desmet et al. [24]. 
 
Genotyping of single nucleotide polymorphism 
Genomic DNA was extracted from whole-blood samples by means of a QIAamp DNA Mini 
Kit according to the manufacturer’s protocol (Qiagen, Tokyo, Japan). The SNP rs 8099917 
of IL28B was genotyped using the TaqMan predesigned SNP genotyping assays, as 
recommended by the manufacturer (Applied Biosystems, Tokyo, Japan). The SNP 
genotypes of all the samples assessed could be obtained with this system. 
 
Statistical analysis 
Data are expressed as the mean ± standard deviation. Differences in HRQOL scores 
between groups were compared by using the Mann-Whitney U test or Spearman's rank 
correlation coefficient. The ratios of patients attaining SVR were compared between the 
groups with the Fisher exact probability test. Stepwise multivariate logistic regression 
Matsushita et al. HRQOL and PegIFN for HCV 9 
 
analysis was utilized to estimate the effects of patient characteristics on SVR and the 
associations of patient characteristics with the HRQOL scores. In the logistic regression 
analysis of the factors related to the therapeutic outcomes of PegIFN and ribavirin therapy, 
the cut-offs of the factors were determined by evaluating the efficacy with the receiver 
operating characteristic area curve. A value of P <0.05 was considered significant. 
Statistical analysis was performed with JMP software (SAS Institute, Cary, NC). 
 
Results 
 
The patient characteristics associated with HRQOL 
The present study enrolled 228 patients (114 male and 114 female) with a mean age of 56 ± 
11 years. The patient characteristics are shown in Table 1. Of those patients, 152 patients 
had HCV serotype 1, and 76 had serotype 2. The genotype of the SNPs rs 8099917 of 
IL28B were TT in 164 patients (74%) and TG or GG in 59 patients (26%). In terms of 
HRQOL, physical component, and its comprising subscales of role-physical and general 
health were significantly lower among the patients than the general population (P = 0.037, 
0.002, <0.001, respectively, the Z test), while the HRQOL scores of mental and role-social 
components showed similar scores to the general population. Associations of patient 
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characteristics were evaluated with the HRQOL, as shown in Figure 1. Patients with high 
age tended lower score of physical component, and higher score of mental component than 
those with young age (r = -0.20, P = 0.0034, and r = 0.17, P = 0.011, respectively, 
Spearman's rank correlation coefficient). Low platelet counts were also associated with low 
scores of physical component (r = 0.14, P = 0.036). Mental component differed significantly 
by the SNP types of IL28B (P = 0.036, the Mann-Whitney U test). Gender, HCV serotype, 
and the levels of alanine aminotransferase, and γ-glutamyl transpeptidase did not affect the 
levels of the HRQOL.  
 
Significant impact of HRQOL on the outcome of interferon therapy 
The HRQOL scores among the SVR group were significantly lower than those among the 
group of transient virological response (389 ± 64, and 414 ± 50, respectively, P = 0.027, the 
Mann-Whitney U test). The group of transient virological response did not differ in the 
HRQOL scores significantly from the group of null or partial virological response (402 ± 61, 
P = 0.42). Therefore, the HRQOL score was compared between the SVR and non-SVR 
groups (Table 2). The score of total HRQOL was significantly lower in the SVR group than 
the non-SVR group (P = 0.031), which reflected significantly lower scores of mental 
component and its comprising subscales in the SVR group than the non-SVR group. The 
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impact of HRQOL on SVR was also assessed in the logistic regression analysis, and 
HRQOL score was inversely correlated to SVR (P = 0.028). The cut-off of the HRQOL score 
was determined with the receiver operator characteristic curve, and a cut-off of 400 points 
gave the best sensitivity and specificity (52% and 70%, respectively). Therefore a cut-off of 
400 points, which was the mean scores of total HRQOL of the general population, was used 
in further logistic regression analysis. The ratio of the patients attaining a SVR was 
significantly higher among the patients with the HRQOL scores <400 points than those with 
HRQOL scores ≥400 points (72% and 52%, P = 0.0038, the Fisher exact probability test). 
Similarly, significant differences in the SVR rate were obtained among the patients with HCV 
serotype 1 and those with HCV serotype 2 (62% vs. 45%, P = 0.048, and 91% vs. 67%, P = 
0.025, respectively). As shown in Table 3, stepwise multivariate logistic regression analysis 
by using the patient characteristics including HRQOL score showed that low HRQOL score 
≤400 points was significantly associated with SVR (odds ratio = 2.4, P = 0.013), 
independently from high platelet counts, low HCV RNA, favorable SNP type of IL28B, and 
HCV serotype 2. When the 3 components of HRQOL were used for the analysis instead, 
mental component score (MCS) was also selected as the significant predictor of SVR (odds 
ratio = 2.4, P = 0.0048). The receiver operating characteristic area curves, constructed from 
the results of the multivariate logistic regression analysis, showed the area under the curve 
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was 0.81 with total HRQOL score, while 0.80 with MCS, showing superior applicability of 
total HRQOL score to MCS. In addition, subgroup analysis for the patients with HCV 
serotype 1 was done. The cut-off of the HRQOL score was determined as 415 points with 
the receiver operator characteristic curve. Stepwise multivariate logistic regression analysis 
showed that low HRQOL score ≤415 points was significantly associated with SVR (odds 
ratio = 2.3, P = 0.039), independently from low levels of γ-glutamyl transpeptidase, high 
platelet counts, and favorable SNP type of IL28B (Table 4). The adherence of PegIFN and 
ribavirin did not differ between the patients with high and low HRQOL scores prior the 
treatment; greater than 80% of the scheduled dose of PegIFN was received by 63% of the 
patients with high HRQOL score, and by 72% of the patients with low HRQOL score (P = 
0.28, the Fisher exact probability test), while greater than 80% of the scheduled dose of 
ribavirin was received by 61% of the patients with high HRQOL score and 66% of the 
patients with low HRQOL score (P = 0.57). The incidence of treatment discontinuation did 
not differ between the patients with high and low HRQOL scores prior the treatment; 19.1% 
of the patients with high HRQOL score, and 14.4% of the patients with low HRQOL score (P 
= 0.38, the Fisher exact probability test).  
 
Changes of HRQOL during IFN therapy 
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One hundred and seventy-six patients were longitudinally evaluated for changes of HRQOL 
score. The total scores and the scores of all the three components were decreased in most 
patients by 4 weeks of treatment, and the decreased scores were maintained until the end 
of treatment. The decreases during 4 weeks of the treatment did not differ significantly 
between the SVR and non-SVR groups (P = 0.22, 0.11, and 0.20 and 0.87, respectively, the 
Mann-Whitney U test, Figure 2). No significant difference in the decreases between the start 
and the end of treatment was observed between the two groups. At 24 weeks after the 
treatment, the patients in the SVR group showed higher total score and MCS compared to 
baseline, while the HRQOL scores of the patients in the non-SVR group did not improved to 
the baseline (P <0.001, and <0.001, respectively). As shown in Figure 3, the patients with 
low HRQOL scores had significantly less decrease of HRQOL during 4 weeks of the 
treatment than those with high scores (P = 0.0045), which might reflect the significant 
decreases in physical component score (PCS) and MCS (P = 0.013, and 0.014, 
respectively).  
 
Discussion 
The present study investigated the HRQOL of the patients with chronic hepatitis C in 
physical, mental and social aspects before and during the treatment prospectively, and 
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evaluated the impact of HRQOL as the predictive factors of interferon therapy. The present 
study is the first to clarify that a low HRQOL before treatment is significantly associated with 
SVR to PegIFN therapy and that HRQOL score before treatment is significantly associated 
with changes of HRQOL score during early phase of treatment. It should be noted that the 
HRQOL predict therapeutic outcome independently from HCV serotype, the SNP genotype 
of IL28B, and platelet counts.  
SF-36, the measurement of HRQOL in the present study, is utilized worldwide as a survey 
for HRQOL. It can evaluate HRQOL status precisely using 3 components and 8 subscales. 
The resulting HRQOL scores can be compared with the standard scores generalized by 
general population. In the present study, HRQOL scores of the patients with chronic 
hepatitis C were significantly lower than those of the general population in 2 of 8 subscales, 
indicating that chronic hepatitis C decreases physical aspects of HRQOL. Patients with 
advanced liver diseases exhibit further decreases in HRQOL, reflecting severe fatigue from 
a physical point of view. These results are similar to the previous reports on HRQOL in 
patients with chronic hepatitis C [16, 17]. 
The present study revealed that HRQOL before treatment is significantly associated with 
attaining a SVR to PegIFN therapy for the patients with chronic hepatitis C. Further analysis 
indicated that there are significant differences in the scores of the MCS before treatment 
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between the SVR and non-SVR patients, but not of the PCS or role-social component score. 
These results are consistent with the previous reports on depression during PegIFN therapy 
in different modes of assessments, demonstrating that IFN-induced depression-specific 
symptoms are distinct from general somatic and fatigue symptoms [13, 14], and that 
minimally depressed patients are less likely than mildly and moderately depressed patients 
to attain an antiviral treatment response by evaluating the degree of depression with Beck 
Depression Inventory [15].  
In order to clarify the mechanisms how low HRQOL may contribute to high possibility of 
attaining a SVR, we investigated patient characters in the associations with low HRQOL. 
The patients with favorable SNP of IL28B had significantly lower HRQOL score than those 
with unfavorable SNPs. However, low HRQOL score significantly associated with SVR 
independently from favorable SNP of IL28B with multivariate regression analysis. Therefore 
our results may indicate that HRQOL itself is an independent predictor for the outcome of 
interferon therapy. The association of drug adherence of PegIFN and ribavirin or incidence 
of treatment discontinuation with low HRQOL at baseline was not obvious in the present 
study.  
Interestingly there were significant associations between the HRQOL score at baseline 
and the changes of HRQOL score during early phase of treatment; the patients with low 
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HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the 
treatment than those with high HRQOL score at baseline. The patients with low HRQOL 
score at baseline may tolerate the changes of physical and mental condition with the 
treatment and maintain the HRQOL during the treatment, while the vulnerability to 
aggravating condition during the treatment may be observed in those with high HRQOL 
score. The unfavorable influence of severely decreased HRQOL during IFN treatment are 
consistent with the previous report showing that severe fatigue during the treatment may 
inversely affect therapeutic outcomes [19]. The reason why less decrease in HRQOL score 
was not significantly associated with SVR was not obvious in the present study.  
In conclusion, patients with chronic hepatitis C have lower HRQOL status than the general 
population. Advanced liver diseases may further worsen HRQOL. HRQOL status before 
treatment is one of the significant factors to predict therapeutic outcomes of PegIFN therapy 
independently from HCV serotype, the SNP genotype of IL28B, and platelet counts.  
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Table 1: Patient characteristics of the patients enrolled in the study 
 
Patient characters  HRQOL scales  
Age (years) 56 ± 11
‡ Total HRQOL 396 ± 62
‡ 
Gender (male/female) 114/114 Physical component 49 ± 9
‡ 
ALT (IU/L) 67 ± 54
‡ Mental component 51 ± 9
‡ 
γGTP (IU/L) 55 ± 56
‡ Role-social component 49 ± 12
‡ 
Platelet count (10000 /mm3) 18 ± 6‡ Physical function 50 ± 10
‡ 
HCV serogroup (1/2) 152/76 Role-physical 47 ± 12
‡ 
HCV RNA (log IU/ml) 6.0 ± 0.9‡ Bodily pain 54 ± 10
‡ 
rs 8099917 (TT/TG or GG/NA) 164/59/5 General health 46 ± 10
‡ 
Liver fibrosis 
(stage 1-2/3-4/NA) 
127/55/46 Vitality 51 ± 10
‡ 
Therapeutic outcome 
(SVR/TVR/NVR) 
138/40/50 Social function 49 ± 11
‡ 
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  Role-emotional 49 ± 10
‡ 
  Mental health 51 ± 9
‡ 
 
‡: Mean ± standard deviation.  
HCV, hepatitis C virus; ALT, alanine aminotransferase; γGTP, γ-glutamyl transpeptidase; 
NA, not assessed; SVR, sustained virological response; TVR, transient virological response; 
NVR, null or partial virological response; HRQOL, health related quality of life.  
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Table 2: The HRQOL score and its associations with sustained virological response 
 
HRQOL scale 
SVR 
(N = 138) 
Non-SVR 
(N = 90) 
P 
Total score 389 ± 64
‡ 408 ± 56‡ 0.031 
Physical component 49 ± 10‡ 49 ± 10‡ 0.52 
Mental component 50 ± 9‡ 54 ± 9‡ 0.001 
Role-social component 49 ± 12‡ 49 ± 12‡ 0.69 
Physical function 49 ± 11
‡ 50 ± 10‡ 0.73 
Role-physical 47 ± 13
‡ 48 ± 11‡ 0.47 
Bodily pain 53 ± 10
‡ 54 ± 9‡ 0.91 
General health 45 ± 10
‡ 48 ± 9‡ 0.020 
Vitality 49 ± 10
‡ 54 ± 9‡ 0.001 
Social function 48 ± 11
‡ 50 ± 11‡ 0.0059 
Role-emotional 49 ± 10
‡ 50 ± 10‡ 0.075 
Mental health 50 ± 9
‡ 53 ± 8‡ 0.013 
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‡: Mean ± standard deviation.  
HRQOL, health related quality of life; SVR, sustained virological response.  
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Table 3: Logistic regression analysis of the factors related to the therapeutic outcomes of 
PegIFN and ribavirin therapy. 
 
 Univariate analysis Multivariate analysis 
Factors Odds ratio (Range†) P Odds ratio (Range†) P 
Age (>65 years) 0.55 (0.29-1.0) 0.057 0.64 (0.29-1.4) 0.27 
Gender (male) 1.6 (0.91-2.7) 0.10   
ALT (>80 IU/L) 0.73 (0.40-1.3) 0.32   
γGT (>70 IU/L) 0.43 (0.23-0.81) 0.0082 0.49 (0.24-1.0) 0.062 
Platelet count 
(>150000 /mm3) 
2.5 (1.4-4.3) 0.0015 3.5 (1.8-7.1) <0.001 
HCV RNA 
(>5 Log IU/ml) 
0.34 (0.12-0.95) 0.039 0.23 (0.061-0.85) 0.027 
HCV serotype 
(Serotype 2) 
3.2 (1.7-6.0) <0.001 2.9 (1.4-6.0) 0.0053 
SNP rs 8099917 5.5 (2.9-11) <0.001 8.8 (3.9-20) <0.001 
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(TT = 1) 
Total HRQOL score 
(>400 points) 
0.43 (0.25-0.75) 0.0031 0.43 (0.22-0.83) 0.013 
 
†: 95% confidence interval.  
ALT, alanine aminotransferase; γGT, γ-glutamyl transpeptidase; HCV, hepatitis C virus; 
HRQOL, health related quality of life.  
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Table 4: Logistic regression analysis of the factors related to the therapeutic outcomes of 
PegIFN and ribavirin therapy for the patients with HCV serotype 1. 
 
 Univariate analysis Multivariate analysis 
Factors Odds ratio (Range†) P Odds ratio (Range†) P 
Age (>65 years) 0.42 (0.19-0.92) 0.030 0.53 (0.19-1.4) 0.21 
Gender (male) 1.8 (0.93-3.4) 0.084   
ALT (>80 IU/L) 0.57 (0.26-1.2) 0.16   
γGT (>70 IU/L) 0.38 (0.18-0.81) 0.013 0.36 (0.14-0.89) 0.027 
Platelet count 
(>150000 /mm3) 
2.5 (1.3-4.8) 0.0071 4.6 (2.0-11) <0.001 
HCV RNA 
(>5 Log IU/ml) 
0.33 (0.087-1.3) 0.11   
SNP rs 8099917 
(TT = 1) 
7.4 (3.1-17) <0.001 10 (3.7-28) <0.001 
Total HRQOL score 0.45 (0.27-1.3) 0.016 0.44 (0.20-0.96) 0.039 
Matsushita et al. HRQOL and PegIFN for HCV 29 
 
(>415 points) 
 
†: 95% confidence interval.  
ALT, alanine aminotransferase; γGT, γ-glutamyl transpeptidase; HCV, hepatitis C virus; 
HRQOL, health related quality of life.  
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Figure legends 
 
Figure 1: The patient characteristics associated with HRQOL.  
The HRQOL scores of the patients were plotted by the total score, and the scores of 
physical, mental, and role-social component. The associations of age (Figure 1A) and 
platelet counts (Figure 1B) with HRQOL score were evaluated by Spearman's rank 
correlation coefficient. The difference of HRQOL score were compared for each patient 
group classified by the genotype of rs 8099917 of IL28B by the Mann-Whitney U test in 
Figure 1C.  
 
Figure 2: The changes of HRQOL score during the treatment.  
One hundred and seventy-six patients were longitudinally evaluated for the changes of 
HRQOL during interferon therapy. Their HRQOL scores were assessed before the 
treatment (Pre), at 4 weeks of treatment (4W), at the end of treatment (EOT), and at 24 
weeks after treatment (+24W). Figure 2A shows the mean change of the HRQOL scores of 
the group attaining a sustained virological response (SVR) with the bold line (n = 107), while 
the mean change in HRQOL for the non-SVR group with the dotted line (n = 69). Figure 2B 
shows the mean change of the HRQOL scores of the group with the baseline of HRQOL 
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≤400 points with the bold line (n = 77), while the mean change in HRQOL for the group with 
the baseline of HRQOL >400 points with the dotted line (n = 99). 
 



